Dr Reddy's Expands Semaglutide Generic Franchise, Trims Oncology Pipel

Dr Reddy’s Laboratories is expanding its semaglutide generic franchise while trimming parts of its oncology pipeline as the company sharpens its focus on the fast-growing obesity treatment market and diabetes care segment. The strategic shift reflects how major pharmaceutical companies are prioritizing high-demand therapies amid rising global interest in weight-loss and metabolic health drugs.

The Hyderabad-based drugmaker is increasing investments in semaglutide, the active ingredient used in blockbuster medicines such as Ozempic and Wegovy. With patents expiring in several markets, including India, pharmaceutical companies are rushing to introduce affordable generic semaglutide versions. Industry experts believe lower-cost semaglutide products could improve access to obesity and diabetes treatment for millions of patients, especially in developing countries.

Dr Reddy’s has already secured approvals for generic semaglutide products in select international markets and is expected to strengthen its presence further over the next two years. The company has reportedly filed applications in multiple countries as part of its plan to build a strong global semaglutide portfolio. Analysts say the company’s aggressive expansion highlights the strong long-term growth potential of GLP-1 drugs in both diabetes management and weight-loss treatment.

Also Read : Recognizing Compassion and Care on International Nurses Day

At the same time, Dr Reddy’s is scaling back investments in certain oncology drug development programs. The move is aimed at redirecting resources toward therapies with faster growth potential and wider market demand. Industry observers note that obesity and metabolic health therapies have become one of the most attractive segments in the global pharmaceutical industry due to increasing patient demand and wider physician acceptance.

Competition in India’s semaglutide market has intensified following patent expirations earlier this year. Several domestic pharmaceutical companies, including Sun Pharmaceutical Industries, Zydus Life Sciences, and Glenmark Pharmaceuticals, have also announced or launched generic semaglutide products. Increased competition is expected to reduce treatment costs and make obesity therapies more accessible to middle-income patients.

Global pharmaceutical companies are closely monitoring the evolution of the generic weight-loss drug market as demand continues to rise worldwide. Industry experts believe affordable generic options could significantly expand the number of patients seeking obesity treatment in the coming years.

For Dr Reddy’s, the stronger focus on semaglutide marks an important strategic shift as the company positions itself for the next phase of growth in chronic care and diabetes management therapies.